Cart
sales@molnova.com
SP-146
CAS No. ——
SP-146( —— )
Catalog No. M22413 CAS No. ——
SP-146 is a selective, potent and non-ATP-competitive Aurora B inhibitor(IC50 : 0.316 nM).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 357 | In Stock |
|
| 10MG | 597 | In Stock |
|
| 25MG | 882 | In Stock |
|
| 50MG | 1350 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameSP-146
-
NoteResearch use only, not for human use.
-
Brief DescriptionSP-146 is a selective, potent and non-ATP-competitive Aurora B inhibitor(IC50 : 0.316 nM).
-
DescriptionSP-146 is a selective, potent and non-ATP-competitive Aurora B inhibitor(IC50 : 0.316 nM).
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayCell Cycle/DNA Damage
-
TargetAurora Kinase
-
RecptorAurora B
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number——
-
Formula Weight453.47
-
Molecular FormulaC25H20FN7O
-
Purity>98% (HPLC)
-
SolubilityDMSO:91 mg/mL (200.67 mM)
-
SMILESCn1cc(cn1)c2ccc5c(c2)ncnc5Nc4cccc(NC(=O)Nc3cccc(F)c3)c4
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Lakkaniga R , Zhang L , Belachew B , et al. Discovery of SP-96, the first non-ATP-competitive Aurora Kinase B inhibitor, for reduced myelosuppression[J]. European Journal of Medicinal Chemistry, 2020, 203:112589.
molnova catalog
related products
-
CCT 137690
A potent, orally bioavailable Aurora kinases inhibitor with IC50 of 15/25/19 nM for Aurora A/B/C; displays antiproliferative activity in a range of human tumor cell lines, including SW620 colon carcinoma (GI50=0.30 uM) and A2780 ovarian cancer cell line (GI50=0.14 uM).
-
AT-9283
A multi-targeted kinase inhibitor with potent activity against Aurora A, Aurora B, JAK2, JAK3, and ABL (T315I) with IC50 of 3, 3, 1.2, 1.1, and 4 nM, respectively.
-
CYC-116
A potent and selective Aurora A/Aurora B inhibitor with IC50 of 8.0/9.2 nM; shows >50-fold selectivity over CDK1/2/4/7/9.
